Anti-Caveolin-3 antibody - Caveolae Marker (ab30750)


  • Product nameAnti-Caveolin-3 antibody - Caveolae Marker
    See all Caveolin-3 primary antibodies
  • Description
    Rabbit polyclonal to Caveolin-3 - Caveolae Marker
  • Tested applicationsSuitable for: ICC, IP, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide corresponding to Human Caveolin-3 aa 1-100 conjugated to Keyhole Limpet Haemocyanin (KLH).
    (Peptide available as ab31791)

  • Positive control
    • ab30750 gave a positive signal in the following tissue lysates: Skeletal Muscle (Human) - adult normal tissue Heart (Human) - adult normal tissue Skeletal Muscle (Mouse) Skeletal Muscle (Rat) - normal tissue



Our Abpromise guarantee covers the use of ab30750 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ICC Use at an assay dependent concentration. PubMed: 21680711
IP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration.
WB Use a concentration of 1 µg/ml. Detects a band of approximately 18 kDa (predicted molecular weight: 17 kDa).


  • FunctionMay act as a scaffolding protein within caveolar membranes. Interacts directly with G-protein alpha subunits and can functionally regulate their activity. May also regulate voltage-gated potassium channels. Plays a role in the sarcolemma repair mechanism of both skeletal muscle and cardiomyocytes that permits rapid resealing of membranes disrupted by mechanical stress.
  • Tissue specificityExpressed predominantly in muscle.
  • Involvement in diseaseDefects in CAV3 are the cause of limb-girdle muscular dystrophy type 1C (LGMD1C) [MIM:607801]. LGMD1C is a myopathy characterized by calf hypertrophy and mild to moderate proximal muscle weakness. LGMD1C inheritance can be autosomal dominant or recessive.
    Defects in CAV3 are a cause of hyperCKmia (HYPCK) [MIM:123320]. It is a disease characterized by persistent elevated levels of serum creatine kinase without muscle weakness.
    Defects in CAV3 are a cause of rippling muscle disease (RMD) [MIM:606072]. RMD is a rare disorder characterized by mechanically triggered contractions of skeletal muscle. In RMD, mechanical stimulation leads to electrically silent muscle contractions that spread to neighboring fibers that cause visible ripples to move over the muscle.
    Defects in CAV3 are a cause of cardiomyopathy familial hypertrophic (CMH) [MIM:192600]; also designated FHC or HCM. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in CAV3 are the cause of long QT syndrome type 9 (LQT9) [MIM:611818]. Long QT syndromes are heart disorders characterized by a prolonged QT interval on the ECG and polymorphic ventricular arrhythmias. They cause syncope and sudden death in response to excercise or emotional stress. They can present with a sentinel event of sudden cardiac death in infancy.
    Defects in CAV3 can be a cause of sudden infant death syndrome (SIDS) [MIM:272120]. SIDS is the sudden death of an infant younger than 1 year that remains unexplained after a thorough case investigation, including performance of a complete autopsy, examination of the death scene, and review of clinical history. Pathophysiologic mechanisms for SIDS may include respiratory dysfunction, cardiac dysrhythmias, cardiorespiratory instability, and inborn errors of metabolism, but definitive pathogenic mechanisms precipitating an infant sudden death remain elusive. Long QT syndromes-associated mutations can be responsible for some SIDS cases.
  • Sequence similaritiesBelongs to the caveolin family.
  • Cellular localizationGolgi apparatus membrane. Cell membrane. Membrane > caveola. Potential hairpin-like structure in the membrane. Membrane protein of caveolae.
  • Information by UniProt
  • Database links
  • Alternative names
    • CAV3 antibody
    • CAV3_HUMAN antibody
    • Caveolin 3 antibody
    • Caveolin-3 antibody
    • LGMD1C antibody
    • LQT9 antibody
    • M-caveolin antibody
    • MGC126100 antibody
    • MGC126101 antibody
    • MGC126129 antibody
    • OTTHUMP00000115603 antibody
    • OTTHUMP00000207105 antibody
    • VIP 21 antibody
    • VIP21 antibody
    see all

Anti-Caveolin-3 antibody - Caveolae Marker images

  • All lanes : Anti-Caveolin-3 antibody - Caveolae Marker (ab30750) at 1 µg/ml

    Lane 1 : Human skeletal muscle tissue lysate - total protein (ab29330)
    Lane 2 : Human heart tissue lysate - total protein (ab29431)
    Lane 3 : Mouse skeletal muscle tissue lysate - total protein (ab29711)
    Lane 4 : Skeletal Muscle (Rat) Tissue Lysate - normal tissue (ab29376)

    Lysates/proteins at 20 µg per lane.

    IRDye 680 Conjugated Goat Anti-Rabbit IgG (H+L) at 1/10000 dilution

    Performed under reducing conditions.

    Predicted band size : 17 kDa
    Observed band size : 17 kDa
    Additional bands at : 40 kDa. We are unsure as to the identity of these extra bands.
  • ICC/IF image of ab30750 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab30750, 5µg/ml) overnight at +4°C. The secondary antibody (green) was ab96899 Dylight® 488 goat anti-rabbit IgG (H+L) used at a 1/250 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • Caveolin 3 - Caveolae Marker was immunoprecipitated using 0.5mg Mouse skeletal muscle whole tissue extract, 5µg of Rabbit polyclonal to Caveolin 3 and 50µl of protein G magnetic beads (+). No antibody was added to the control (-).
    The antibody was incubated under agitation with Protein G beads for 10min, Mouse skeletal muscle whole tissue extract lysate diluted in RIPA buffer was added to each sample and incubated for a further 10min under agitation.
    Proteins were eluted by addition of 40µl SDS loading buffer and incubated for 10min at 70oC; 10µl of each sample was separated on a SDS PAGE gel, transferred to a nitrocellulose membrane, blocked with 5% BSA and probed with ab30750.
    Secondary: Clean blot (HRP conjugate) at 1/1000 dilution.
    Band: 17kDa: Caveolin 3 - Caveolae Marker.

References for Anti-Caveolin-3 antibody - Caveolae Marker (ab30750)

This product has been referenced in:
  • Valentine CD & Haggie PM Confinement of ß(1)- and ß(2)-adrenergic receptors in the plasma membrane of cardiomyocyte-like H9c2 cells is mediated by selective interactions with PDZ domain and A-kinase anchoring proteins but not caveolae. Mol Biol Cell 22:2970-82 (2011). Read more (PubMed: 21680711) »
  • Willett M  et al. Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Cell Signal 21:1504-12 (2009). Read more (PubMed: 19481146) »

See all 2 Publications for this product

Product Wall

Application Immunohistochemistry (Frozen sections)
Blocking step Serum as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 5% · Temperature: 22°C
Sample Mouse Tissue sections (Heart)
Specification Heart
Permeabilization Yes - 1% Triton X100+ 0,05% Tween 20 in 1xPBS Buffer
Fixative Acetone

Frau Dr. Galyna Pryymachuk

Verified customer

Submitted Sep 01 2014

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Western blot
Sample Mouse Cell lysate - whole cell (C2C12 myoblast/myotube)
Loading amount 5 µg
Specification C2C12 myoblast/myotube
Treatment Differentiation medium, 0-72 hours
Gel Running Conditions Reduced Denaturing (10-15%)
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 3% · Temperature: 20°C

Dr. Hilary Pollard

Verified customer

Submitted May 20 2011

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Human (uterus) mouse (liver) rat (thymus))
Specification Human (uterus) mouse (liver) rat (thymus)
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate Buffer pH 6.0
Permeabilization No
Blocking step Sequential peroxidase and protein block (prediluted) as blocking agent for 20 minute(s) · Concentration: 100% · Temperature: 20°C

Mr. Antibody Solutions

Verified customer

Submitted Apr 05 2008